-
Slightly above forecasts ive read and div the same , 37c. S/P up on nasdaq.
ASX $13.75 atm. Add on later.S/P up re 6% today .
First Quarter 2019 Highlights
- Revenue increased 12% to $588.3 million; up 13% on a constant currency basis
- Net income increased by 23%; non-GAAP net income up 23%
- GAAP diluted earnings per share of $0.73; non-GAAP diluted earnings per share of $0.81
Last edited by Joshuatree; 26-10-2018 at 01:04 PM.
-
Not far off its high atm wheres FPH is 25% down.
-
- Good result yet again , but is it enough ,S/P at an all time high.
Second Quarter 2019 Highlights
- Revenue increased 8% to $651.1 million; $588.3 mill last qtr, up 9% on a constant currency basis
- Gross Margin expanded 70bps to 58.9%
- Net operating profit increased 8%; non-GAAP operating profit up 15%
- GAAP diluted earnings per share of $0.86; non-GAAP diluted earnings per share of $1.00
-
-
I am viewing the drop as a buying opportunity, topped up at $14.63
-
Resmed CEO Mick Farrell interview with CNBC Amanda Drury
I saw an interview with CEO on CNBC with Mandy Drury after the announcement.
Announcement was positive overall.
Negatives included minor misses of some expectations and their share buy back programme was halted.
CEO explained they had made $1.5B aquisitions and wanted trading to restore cash before resuming SBB. They have suspended SBB before after aquisitions.
This year takeovers included Matrixcare and Bright Tree health software. Resmed launched new products Moby (?) a liteweight portable oxygen supply innovation where Resmed will supply the unobtrusive face masks. This will enable house bound elderly requiring oxygen to go shopping etc. CEO explained people will spend on devices that provide health and life style benefits, even in bad times.
He also spoke of the new improved Resmed masks M30-1 and F30.
Above from memory E&OE. Decided at this point to find the video and post the link.
At face value positive for SPP as acquisitions additional revenue increases.
https://www.cnbc.com/video/2019/01/2...alth-care.html
Apologies as CNBC clips usually have an ad before they run ...
-
-
I sold some more @$15.91. They were priced for perfection (and have been on a pedestal for some time), whether they rerate back up there to their lofty PE heights for a best in breed stock im not so sure in 2019 because of the uncertainty re the mkts on a slide down this year.? I hope they do rerate, in a flight to quality/safety sorta way. FPH dragged down too.
-
Originally Posted by Joshuatree
I sold some more @$15.91. They were priced for perfection (and have been on a pedestal for some time), whether they rerate back up there to their lofty PE heights for a best in breed stock im not so sure in 2019 because of the uncertainty re the mkts on a slide down this year.? I hope they do rerate, in a flight to quality/safety sorta way. FPH dragged down too.
I sold some recently at $15.45 and then regretted it so I was quite pleased to buy them back at $14.63, not feeling quite so pleased now but trying to convince myself they will be a good long term hold but hard to know with the current uncertainty.
-
Download Document 84.1KB
New high s/p up 14% to $21 (back little now). May take some $ and put more into junior OVN. Over 50% of users give up the cpap masks within a year, OVN offer an alternative.
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
-
Forum Rules
|
|
Bookmarks